Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE nhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Novalia P. Sidik , Scott D. Solomon , Roberto Latini , Aldo P. Maggioni , Melanie Wright ,Claudio R. Gimpelewicz , Bertram Pitt , John J. V. McMurray
- چاپ و سال / کشور: 2011
Description
Aims To compare the effect of the direct renin inhibitor aliskiren on neurohumoral activity in heart failure patients treated with low-dose and high-dose ACE inhibitor. Methods A retrospective analysis of the ALOFT trial. Comparison of the effects of 6 months treatment with aliskiren (versus placebo) in patients receiving <guidelinerecommended dose of ACE inhibitor (n=109) with those receiving . recommended-dose (n=81). Neurohumoral measures included B-type natriuretic peptide (BNP), NT proBNP, plasma renin activity and urinary aldosterone excretion. Results Patients in each ACE inhibitor-dose group were generally similar (those in the . recommended ACE inhibitor-dose had higher baseline blood-pressures and LVEF and were more often female and diabetic). In the <recommended-dose sub-group, the reduction in BNP from baseline to end-of-study was .1% (95% CI .32 to +44%) in the placebo-group and .32% (.1 to .53%) in the aliskiren group. The corresponding reductions in the .recommended ACE inhibitor-dose sub-group were: placebo .19% (.46 to +22%) and aliskiren .46% (.22 to .62%); interaction p-value 0.94. The pattern of results for other neurohumoral markers was similar. Conclusions Aliskiren causes neurohumoral suppression in heart failure, even in patients treated with .recommended-dose of ACE inhibitor.
Cardiovasc Drugs Ther (2011) 25:315–321 Published online: 21 July 2011
